Shanghai Henlius Biotech (HKSE:02696) Cash-to-Debt : 0.16 (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Shanghai Henlius Biotech's cash to debt ratio for the quarter that ended in Jun. 2024 was 0.16.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Shanghai Henlius Biotech couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Shanghai Henlius Biotech's Cash-to-Debt or its related term are showing as below:

HKSE:02696' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06 Med: 0.24 Max: 3.78
Current: 0.16

During the past 7 years, Shanghai Henlius Biotech's highest Cash to Debt Ratio was 3.78. The lowest was 0.06. And the median was 0.24.

HKSE:02696's Cash-to-Debt is ranked worse than
92.67% of 1487 companies
in the Biotechnology industry
Industry Median: 6.4 vs HKSE:02696: 0.16

Shanghai Henlius Biotech Cash-to-Debt Historical Data

The historical data trend for Shanghai Henlius Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Shanghai Henlius Biotech Cash-to-Debt Chart

Shanghai Henlius Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

3.78

0.61

0.06

0.19

0.24

Shanghai Henlius Biotech Quarterly Data
	Dec17	Mar18	Jun18	Dec18	Mar19	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Jun24
Cash-to-Debt	Get a 7-Day Free Trial													0.19	0.20	0.18	0.24	0.16

Competitive Comparison of Shanghai Henlius Biotech's Cash-to-Debt

For the Biotechnology subindustry, Shanghai Henlius Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Henlius Biotech's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Shanghai Henlius Biotech's Cash-to-Debt falls into.

Shanghai Henlius Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Shanghai Henlius Biotech's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1080.287	/	(3062.993	+	1413.9)
	=	0.24

Shanghai Henlius Biotech's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	699.16	/	(3054.927	+	1309.476)
	=	0.16

Shanghai Henlius Biotech (HKSE:02696) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Shanghai Henlius Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Henlius Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233

Website

https://www.henlius.com

Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.

Executives

Qatar Investment Authority	2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited	2101 Beneficial owner
Shanghai Fosun Pharmaceutical (group) Co., Ltd.	2201 Interest of corporation controlled by you
Fosun Holdings Limited	2201 Interest of corporation controlled by you
Fosun International Holdings Ltd.	2201 Interest of corporation controlled by you
Fosun International Limited	2201 Interest of corporation controlled by you
Guo Guangchang	2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd.	2201 Interest of corporation controlled by you
Liu Scott Shi-kau	2201 Interest of corporation controlled by you
Jiang Wei-dong	2201 Interest of corporation controlled by you
Henlius Biopharmaceuticals, Inc.	2101 Beneficial owner

Shanghai Henlius Biotech Headlines

No Headlines